Your browser doesn't support javascript.
loading
Underdetection of cases of COVID-19 in France threatens epidemic control.
Pullano, Giulia; Di Domenico, Laura; Sabbatini, Chiara E; Valdano, Eugenio; Turbelin, Clément; Debin, Marion; Guerrisi, Caroline; Kengne-Kuetche, Charly; Souty, Cécile; Hanslik, Thomas; Blanchon, Thierry; Boëlle, Pierre-Yves; Figoni, Julie; Vaux, Sophie; Campèse, Christine; Bernard-Stoecklin, Sibylle; Colizza, Vittoria.
  • Pullano G; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.
  • Di Domenico L; Orange Labs, Sociology and Economics of Network and Services (SENSE), Chatillon, France.
  • Sabbatini CE; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.
  • Valdano E; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.
  • Turbelin C; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.
  • Debin M; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.
  • Guerrisi C; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.
  • Kengne-Kuetche C; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.
  • Souty C; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.
  • Hanslik T; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.
  • Blanchon T; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.
  • Boëlle PY; UFR des Sciences de la Santé Simone-Veil, Université Versailles-Saint-Quentin-en-Yvelines, Versailles, France.
  • Figoni J; AP-HP, Service de Médecine Interne, Hôpital Ambroise Paré, Boulogne Billancourt, France.
  • Vaux S; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.
  • Campèse C; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.
  • Bernard-Stoecklin S; Santé publique France, Direction des maladies infectieuses, Saint-Maurice, France.
  • Colizza V; Santé publique France, Direction des maladies infectieuses, Saint-Maurice, France.
Nature ; 590(7844): 134-139, 2021 02.
Article en En | MEDLINE | ID: mdl-33348340
As countries in Europe gradually relaxed lockdown restrictions after the first wave, test-trace-isolate strategies became critical to maintain the incidence of coronavirus disease 2019 (COVID-19) at low levels1,2. Reviewing their shortcomings can provide elements to consider in light of the second wave that is currently underway in Europe. Here we estimate the rate of detection of symptomatic cases of COVID-19 in France after lockdown through the use of virological3 and participatory syndromic4 surveillance data coupled with mathematical transmission models calibrated to regional hospitalizations2. Our findings indicate that around 90,000 symptomatic infections, corresponding to 9 out 10 cases, were not ascertained by the surveillance system in the first 7 weeks after lockdown from 11 May to 28 June 2020, although the test positivity rate did not exceed the 5% recommendation of the World Health Organization (WHO)5. The median detection rate increased from 7% (95% confidence interval, 6-8%) to 38% (35-44%) over time, with large regional variations, owing to a strengthening of the system as well as a decrease in epidemic activity. According to participatory surveillance data, only 31% of individuals with COVID-19-like symptoms consulted a doctor in the study period. This suggests that large numbers of symptomatic cases of COVID-19 did not seek medical advice despite recommendations, as confirmed by serological studies6,7. Encouraging awareness and same-day healthcare-seeking behaviour of suspected cases of COVID-19 is critical to improve detection. However, the capacity of the system remained insufficient even at the low epidemic activity achieved after lockdown, and was predicted to deteriorate rapidly with increasing incidence of COVID-19 cases. Substantially more aggressive, targeted and efficient testing with easier access is required to act as a tool to control the COVID-19 pandemic. The testing strategy will be critical to enable partial lifting of the current restrictive measures in Europe and to avoid a third wave.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Portador Sano / Prueba de COVID-19 / COVID-19 / Modelos Biológicos Tipo de estudio: Incidence_studies / Prognostic_studies Límite: Female / Humans / Male País como asunto: Europa Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Portador Sano / Prueba de COVID-19 / COVID-19 / Modelos Biológicos Tipo de estudio: Incidence_studies / Prognostic_studies Límite: Female / Humans / Male País como asunto: Europa Idioma: En Año: 2021 Tipo del documento: Article